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ABSTRACT
Introduction: Zoon’s balanitis, also referred to
as balanitis circumscripta plasmacellularis
(BCP), is an idiopathic, benign inflammatory
condition of the glans penis and foreskin most
often seen in elderly uncircumcised men. A
patient with a biopsy-confirmed diagnosis of
BCP who was successfully treated with topical
mupirocin ointment is described.
Methods: The PubMed database was searched
with the key words: bactroban, balanitis, cell,
circumscripta, mupirocin, plasma, plasmacellu-
laris, tacrolimus, Zoon. The papers generated by
the search and their references were reviewed.
Results: Treatments for BCP have previously
included circumcision and topical calcineurin
inhibitors. Our patient with BCP rapidly
resolved after initiating treatment with mupir-
ocin 2% ointment.
Conclusion: BCP is a benign dermatosis affect-
ing the glans penis and foreskin. We confirm an
earlier observation demonstrating successful
management of this condition with topical
mupirocin 2% ointment. Previously reported
therapies include circumcision, topical cal-
cineurin inhibitors, phototherapy, and laser
therapy. However, based on our observations,
topical mupirocin 2% ointment therapy may be
considered for the initial management of
patients with suspected BCP. Prompt response
to mupirocin 2% ointment is highly suggestive
of the diagnosis of BCP since morphologically
similar skin conditions do not respond to this
treatment.




In 1952, Zoon described eight men with chronic
balanitis who were initially diagnosed with
erythroplasia of Querat [1]. Histological assess-
ment of these lesions revealed extensive infil-
tration of plasma cells. However, the lesions
lacked cytological atypia and dysplasia of the
epidermis; thus, Zoon reported the condition as
circumscribed plasma cell balanoposthitis. Sub-
sequently, the condition has been referred to as
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Zoon’s balanitis, but is also known as balanitis
circumscripta plasmacellularis (BCP) [2].
BCP is not common. Indeed, it often pro-
vides a therapeutic challenge once the diagnosis
is established. A man with biopsy-confirmed
BCP is described whose condition rapidly
improved after initiating topical therapy with
mupirocin 2% ointment. All procedures fol-
lowed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from the patient for being included in
the study.
CASE REPORT
A 51-year-old healthy, heterosexual, monoga-
mous man presented for evaluation of an
asymptomatic red lesion on his foreskin and
glans penis. He had no history of sexually
transmitted disease or HIV-associated risk fac-
tors. He presented with a 2-year history of
intermittent pruritus at the site of the rash on
his penis. He had been previously treated with
clotrimazole 1% cream without improvement.
Clinical exam revealed an uncircumcised
male. Retraction of the foreskin demonstrated a
confluent, erythematous, erosive, mucosal pla-
que on the lateral and dorsal glans penis,
extending to involve the coronal and adjacent
prepuce (Fig. 1). The differential diagnosis
included autoimmune bullous disease, BCP,
candidiasis, dermatitis, erythroplasia of Querat,
and lichen planus.
Microscopic examination of the biopsy from
the glans penis revealed a submucosa with a
band-like infiltrate composed of abundant
lymphocytes and plasma cells (Fig. 2). Paraker-
atosis and occasional neutrophils were also
evident in the superficial epithelium. Correla-
tion of the patient’s history, lesional morphol-
ogy, and pathologic changes established a
diagnosis of BCP.
After the biopsy was performed, but prior to
receiving results, the biopsy site and surround-
ing affected mucosa were treated with mupir-
ocin 2% ointment three times daily. In
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addition, although not previously effective,
clotrimazole 1% was applied twice daily. When
the patient was contacted by telephone with
the biopsy results 12 days later, he commented
that there had been a dramatic improvement of
his dermatosis with the new topical therapy. He
stopped the antifungal cream and continued
with mupirocin ointment.
Treatment with topical mupirocin resulted
in the lesion’s clearance within 6 weeks of use.
When he subsequently discontinued therapy,
the lesion began to reappear. At his return visit,
3 months later, there was near complete reso-
lution with focal residual erythematous plaques
(Fig. 3). The residual lesions promptly resolved
within a month once treatment with mupirocin
2% ointment was reinitiated.
DISCUSSION
BCP is a benign inflammatory dermatosis
affecting the penis and foreskin in uncircum-
cised men. The age of onset has been observed
to range from 20 to 91 years, though BCP most
often occurs in elderly men; previously, the
mean age of 20 patients with BCP was found to
be 64.8 years [2–5]. The lesions are chronic and
typically present for 1–2 years prior to diagnosis
[6]. Similar clinical features are observed in
women with vulvitis circumscripta plasmacel-
lularis [7].
BCP clinically presents as erythematous pla-
ques involving the glans, prepuce, or both.
Typically the condition is asymptomatic,
though pruritus or tenderness may be present
[2, 8]. The lesions may occur co-incident or
independent of intercourse [9]. The differential
diagnosis for long-lasting erythematous penile
lesions is summarized in Table 1 [2, 9, 10].
The histopathology in BCP reveals a band-
like infiltrate of plasma cells in the submucosa
[1]. Atrophy of the mucosa, loss of the rete rid-
ges, spongiosis, dilated vessels, mild fibrosis,
and hemosiderin deposition have also been
reported [2, 9, 11]. Notably, there is no ker-
atinocyte dysplasia or frank vesiculation [6].
Similar lesions in other mucosal sites, such as
the vaginal, perianal, and oral regions, have
been reported [7, 12, 13]. Reflectance confocal
microscopy may help avoid penile biopsy by
differentiating between balanitis and carcinoma
in situ [14].
Several treatment modalities have been
described to manage patients with BCP. A series
bFig. 1 Distant (a, b) and closer (c, d) views of erythema-
tous, shiny, conﬂuent red plaque on the lateral and dorsal
glans penis with extension to the adjacent foreskin
Fig. 2 Low (a), medium (b), and higher (c) magniﬁcation
views of biopsy from glans penis. Focal loss of superﬁcial
mucosa from underlying submucosa is evident in the
low-magniﬁcation view. The submucosa reveals an inﬁl-
trate of lymphocytes and plasma cells. The superﬁcial
epithelium reveals parakeratosis and rare neutrophils
(hematoxylin and eosin; a 94; b 920; c 940)
Dermatol Ther (Heidelb)
of patients treated by a single provider are
uncommon, as most reports of BCP are indi-
vidual cases [15]. Previously, first-line therapy
has been circumcision, since the absence of
foreskin removes a nidus of chronic inflamma-
tion [16, 17].
Nonsurgical intervention has been reported,
which is an important consideration since
patients often reject procedures in this sensitive
area [21]. Some cases have shown efficacy with
griseofulvin, fusidic acid, or corticosteroids.
However, established therapeutic efficacy of
these agents has not been repeatedly confirmed
in BCP [15, 22, 23]. Cryotherapy has also been
used; however, this therapy is associated with
little to no response [20].
More recently, other therapeutic modalities
have been used, including photodynamic and
laser therapy [3, 18–20]. Photodynamic therapy,
which has been used in refractory lesions,
involves the application of topical porphyrin
precursors (5-aminolaevulinic acid or methyl
aminolevulinate) and subsequent exposure to a
light source whose wavelength is appropriate
for exciting the photosensitizing chemical sub-
stance [20]. The mechanism of action has not
been fully elucidated; it is thought that acti-
vated T-lymphocytes are sensitive to photody-
namic therapy, which leads to inhibition of
Fig. 3 Distant (a) and closer (b, c) views of the previously
affected glans penis and foreskin after mupirocin 2%
ointment treatment. The large conﬂuent plaque is almost
completely resolved, with small remnants of erythema
Table 1 Differential diagnosis of erythematous penile







Lichen sclerosis et atrophicus
Pemphigus vulgaris




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cytokines that attract plasma cells to the dermis
[20]. To date, phototherapy has been well tol-
erated with no long-term adverse effects repor-
ted [20]. Carbon dioxide and erbium:YAG lasers
have been shown to be viable treatment options
which are less traumatic than circumcision;
both lasers offer precise ablation and have been
well tolerated by patients [20].
Recently, several reports of calcineurin inhi-
bitors, tacrolimus 0.1 and 0.03% and pime-
crolimus 0.1%, have been described in the
literature. Kyriakou et al. published a case series
along with a review of nine reports of cal-
cineurin inhibitor use [21]; the 30 patients
reviewed applied a calcineurin inhibitor and
experienced improvement or complete resolu-
tion after 3–8 weeks of therapy onset. Response
was maintained in 22 of 23 patients with fol-
low-up data of 3 months or more [21]. One
patient was treated with circumcision after
3 months of calcineurin inhibitor therapy [21].
In addition to our patient, we are aware of
one other man whose BCP was successfully
treated with mupirocin 2% ointment (Table 2)
[11]. He was a 62-year-old healthy, heterosexual
male with a red lesion on his foreskin and glans
penis. His primary care physician initially trea-
ted him with clotrimazole 1% cream, which
improved the rash on the glans penis but not on
the foreskin. Tacrolimus 0.1% ointment was
prescribed, but due to an unexpected delay in
receiving the medication, he continued to use
mupirocin three times a day similarly to how he
treated his biopsy site prior to suture removal.
Complete resolution of the lesion was seen fol-
lowing 3 months of mupirocin monotherapy.
Our patient experienced prompt resolution
of his rash after starting mupirocin 2% oint-
ment similar to the previously reported patient.
Topical antifungal medication had been used
previously without success in our patient. Also,
similar to the previous patient, our patient’s
dermatosis recurred if mupirocin therapy was
discontinued. Thus, he has been maintained on
mupirocin 2% ointment with instructions to
taper the frequency of application.
The pathogenesis of BCP remains to be estab-
lished. Successful management with mupirocin,
an antibiotic that blocks protein synthesis, raises
the possibility that BCP may directly or indirectly
be implicated with bacterial infection or
super-antigen [11, 24]. Other postulated mecha-
nisms of pathogenesis include: chronic irritant
contact dermatitis due to chronic Mycobacterium
smegmatis infection, foreskin inflammation, fric-
tion, heat, hypospadias, IgE-antibody-mediated
hypersensitivity response, lack of hygiene, non-
specific polyclonal stimulation of B cells, penile
trauma, pre-malignancy, and T cell-mediated
damage [2, 11, 25–31].
CONCLUSIONS
BCP is an uncommon benign dermatosis
affecting the glans penis, foreskin, or both. The
condition predominantly occurs in uncircum-
cised elderly men. Although circumcision was
the gold standard therapy, more recently topi-
cal calcineurin inhibitors have been shown to
be efficacious. Our observation confirms a pre-
vious report of successful management of BCP
with topical mupirocin 2% ointment. The rapid
and dramatic response to this therapy might
also be used as a diagnostic test since other
similar-appearing dermatoses lack response to
this agent. In conclusion, we suggest not only
that mupirocin 2% ointment may be used to
confirm a suspected diagnosis of BCP prior to
biopsy but also that the drug can be used pos-
sibly as initial monotherapy for resolution with
periodic maintenance therapy as needed to
preserve clearance of this condition.
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